Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medcli.2009.07.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system.
Front Pharmacol
March 2024
Department of Breast Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Everolimus is an inhibitor of the mammalian target of rapamycin and is used to treat various tumors. The presented study aimed to evaluate the Everolimus-associated adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). The AE records were selected by searching the FDA Adverse Event Reporting System database from the first quarter of 2009 to the first quarter of 2022.
View Article and Find Full Text PDFClinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis.
J Nippon Med Sch
May 2024
Department of Pulmonary Medicine and Oncology, Nippon Medical School.
Article Synopsis
- Everolimus, an anti-cancer drug, is linked to a high rate of interstitial lung disease (ILD), but its clinical and pathological effects are not well studied.
- A study analyzed medical records of 66 patients treated with everolimus, finding that 19 developed ILD, with varying severity but no demographic differences between affected and unaffected patients.
- Chest CT scans indicated patterns like organizing pneumonia, and higher biomarkers correlated with ILD onset, while lung biopsies revealed significant inflammatory features; overall, ILD from everolimus is generally mild and tends to have a good prognosis.
Life-Threatening Everolimus-Associated Pneumonitis: A Case Report and a Review of the Literature.
Transplant Proc
April 2018
Infectious Diseases Department, Centro Hospitalar de São João, Porto, Portugal.
Introduction: Noninfective pneumonitis is a class-related effect within mammalian target of rapamycin (mTOR) inhibitors, including everolimus, and can occasionally be severe.
Case Report: A 62-year-old man, medicated with everolimus due to a heart transplantation 17 years previously and with chronic kidney disease, was admitted to the intensive care unit (ICU) with acute respiratory failure, cardiovascular shock, and impaired renal function requiring dialysis. Computed tomography (CT) scan revealed right upper lobe consolidation.
Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.
Orphanet J Rare Dis
February 2017
Sussex Kidney Unit, Royal Sussex County Hospital, Eastern Road, Brighton, BN2 5BE, UK.
Tuberous sclerosis complex (TSC) is a genetic disorder characterised by highly variable comorbid dysfunction and subsequent morbidity. The mTOR inhibitor everolimus is indicated for the treatment of adult TSC patients with renal angiomyolipomas (AMLs) and for subependymal giant astrocytoma (SEGA) in both adults and children, based on data from the EXIST-1 and EXIST-2 trials. However, due to the historical predominance of everolimus in the oncology setting, some physicians who treat TSC patients may be unfamiliar with everolimus-associated adverse events (AEs) and appropriate management strategies.
View Article and Find Full Text PDFEverolimus associated interstitial pneumonitis in a liver transplant patient.
Respir Med Case Rep
July 2016
Division of Critical Care, Houston Methodist Hospital, 6565 Fannin St, Houston, TX 77030, USA.
Drug-induced interstitial lung disease is associated with significant morbidity and mortality. Everolimus is an inhibitor of mTOR, a mammalian target of rapamycin, used as an immunosuppressant agent in solid organ transplant. Everolimus has been associated with interstitial lung disease in solid organ transplant patients but has been rarely reported in the liver transplant patient population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!